Swipha
Swipha is a Nigerian pharmaceutical manufacturer (subsidiary of India's Micro Labs) producing 50+ SKUs across anti-malarial, anti-infective, anti-diabetic, cardiovascular, and CNS categories, serving hospitals, pharmacies, and government health programs in Nigeria and West Africa.
- Company typePrivate
- Founded1976
- HeadquartersLagos, Nigeria
- Headcount5,001–10,000
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Swipha does
Swipha (legal entity: Swiss Pharma Nigeria Limited) is a Lagos-based pharmaceutical manufacturer founded in 1976 by F. Hoffmann-La Roche, Switzerland, that has operated as a premium branded generics producer in Nigeria since 1999 and became a wholly-owned subsidiary of India's Micro Labs in 2024. The company manufactures over 50 SKUs and 30+ brands across five therapeutic categories — Anti-diabetes, Anti-infectives, Anti-malarial, Central Nervous System, and Cardiovascular — at a single manufacturing facility located at 5 Dopemu Road, Agege, Lagos State. Its consumer health portfolio includes nutritional supplements (SupraFem, SupraFit, SupraKIDS) and OTC products (Polyfort, Swifen, Expezol), while its prescription portfolio spans antimalarials (Arenax Plus, Dyrax), antibiotics (Swipha Azithromycin, Cefuroxime), antidiabetics (Metformin, Glipizide), cardiovascular agents (Amlodipine, Rosuvastatin), and CNS medications.
The company operates a conventional pharmaceutical manufacturing stack (V-Blender, Shear Mixer, HPLC, compression, coating, blistering, liquid manufacturing lines, dissolution, purified water processing) supplemented by a pharmacovigilance monitoring platform that provides end-to-end product traceability through the distribution channel. Swipha holds Nigeria-first ISO 9001:2008 certification (2008), West Africa-first WHO cGMP certification (2014), and Africa-first WHO prequalification for a finished pharmaceutical product (Pediatric Zinc Sulphate, 2023), followed by a second WHO prequalification for Sulfadoxine-Pyrimethamine (2024).
The business model is sales-led and prescription-driven: Swipha sells directly to hospitals, clinics, and pharmacies through a 100+ member sales force, distributes consumer products via retail pharmacy wholesale, and supplies government health programs (including the Nigerian National Malaria Elimination Programme) directly. Revenue is generated through one-time product sales; pricing is not publicly disclosed. Customer segments span healthcare providers, retail pharmacy end-patients, pregnant women (via WHO-prequalified SP), and pediatric patients (via WHO-prequalified Zinc Sulphate). The company leverages partnerships with NAFDAC, MMV, Unitaid, USP, and Global Fund/USAID pursuit channels to access donor-funded procurement.
Swipha firmographics
Firmographics- Name
- Swipha
- Legal name
- Swiss Pharma Nigeria Limited
- Website
- https://swiphanigeria.com
- Company type
- Private
- Founded year
- 1976
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Swipha is a Nigerian pharmaceutical manufacturer (subsidiary of India's Micro Labs) producing 50+ SKUs across anti-malarial, anti-infective, anti-diabetic, cardiovascular, and CNS categories, serving hospitals, pharmacies, and government health programs in Nigeria and West Africa.
- Ownership category
- akta.pro rank
Swipha industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industries
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)
Keywords
Where Swipha is headquartered
LocationHeadquarters
- HQ city
- Lagos
- HQ country
- Nigeria
- HQ region
- Africa
Offices1 record
Markets served
Swipha business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Sale of prescription and consumer healthcare pharmaceutical products across five major therapeutic classes including Anti-diabetes, Anti-infectives, Anti-malarial, Central Nervous System and Cardiovascular. Products include over 50 SKUs and over 30 brands.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
Swipha product offering
Product offeringCore offering
Swipha (Swiss Pharma Nigeria Limited) manufactures and distributes a portfolio of over 50 SKUs and 30+ brands of prescription and consumer healthcare pharmaceutical products across five major therapeutic categories: Anti-diabetes, Anti-infectives, Anti-malarial, Central Nervous System, and Cardiovascular. The company operates a WHO cGMP-certified manufacturing facility in Lagos, Nigeria, producing WHO-prequalified medications and serving healthcare providers, pharmacies, and government health programs in Nigeria and West Africa.
Product overview
Swiss Pharma Nigeria Limited (Swipha) is a pharmaceutical company manufacturing a comprehensive portfolio of prescription medicines and consumer healthcare products across five major therapeutic categories: Anti-diabetes, Anti-infectives, Anti-malarial, Central Nervous System (CNS), and Cardiovascular (CVS). The company produces over 50 SKUs and 30+ brands. Key prescription products include antimalarials (Arenax Plus, Dyrax, Swidar), antibiotics (Ocefix, Swipha Azithromycin, Swipha Cefuroxime), antidiabetics (Clabetic, Swipha Metformin, Swibetic), cardiovascular medications (Swipha Amlodipine, Cardiotan, Clopidogrel, Rosuvastatin), and CNS medications. Consumer/healthcare products include nutritional supplements (SupraFem, SupraFem Plus for prenatal care, SupraFit, SupraFit Men, SupraFit Women), pediatric products (SupraKIDS Syrup, SupraKIDS Drops), and over-the-counter medications (Polyfort, Swifen, Expezol). The company achieved WHO prequalification for two products: Pediatric Zinc Sulphate 20mg dispersible tablet and Sulfadoxine Plus Pyrimethamine for malaria prevention in pregnancy.
Differentiator
Problem solved
Functional benefit
Brands
- Swipha Pharmaceuticals: Primary brand for prescription medicines and consumer healthcare products
Products and services
- Arenax Plus Forte
Quantifiable outcome
- First company in Africa to obtain WHO Pre-qualification for Zinc 20 mg Dispersible Tablet
- +1 more outcomes
Companies that use Swipha
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Swipha technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Swipha partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Medicines for Malaria Venture (MMV)coreProvided technical and dossier support for WHO prequalification of Sulfadoxine-Pyrimethamine. MMV has over 18 years experience supporting local manufacturing that meets WHO quality standards and works with pharmaceutical manufacturers in malaria-endemic countries to reinforce their capacity to produce quality medicines.
- NAFDACcoreNational regulatory agency for food and drug administration in Nigeria. Provided regulatory support and collaboration that enabled Swipha to achieve WHO prequalification. NAFDAC Director General Prof. Mojisola Adeyeye commended Swipha for its achievement.
- Nigerian National Malaria Elimination ProgrammecoreGovernment body responsible for malaria elimination in Nigeria. Elated about Swipha's attainment of WHO prequalification, stating it promises to have tremendous impact on the Nigerian health system by increasing availability of quality-assured medicines.
- Servier Generic GroupcorePart of the Servier Group, aligned with Swipha's mission to care through action and promote community-interest activities. Servier Group values (Commit to Succeed, Dare to Innovate, Grow by Sharing, Care) guide Swipha's corporate responsibility initiatives.
- Global FundminorInternational financing institution that purchases drugs for distribution to countries with high disease burden. Swipha is seeking partnerships with Global Fund and USAID to tackle critical health challenges like Malaria.
- United States Pharmacopoeia (USP)minorScientific organization that develops standards for medicines. Part of the USP-PQM+ program that played a crucial role in making WHO prequalification possible.
- Micro LabscoreSwipha became a subsidiary of Micro Labs in 2024. Micro Labs is a multinational pharmaceutical company with presence in over 50 countries and having over 40 WHO prequalified products in various therapeutic areas.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Swipha competitors and assessment
Company assessmentBroad incumbents
- Sanofi Nigeria: Multinational pharma with Nigerian operations across prescription generics, vaccines and consumer health in cardiovascular, diabetes, anti-infectives and CNS — directly overlapping Swipha's therapeutic footprint as a global incumbent rather than a regional generics specialist.
- Cipla (African operations): Indian multinational generics giant with active West African sales including ARVs, antimalarials and respiratory products; competes with Swipha on cost-leadership generic molecules and operates regional manufacturing partners in Africa.
- GlaxoSmithKline (GSK Nigeria): Multinational pharma with Nigerian operations selling branded pharmaceuticals and consumer health across anti-infectives, pain and respiratory — overlapping with Swipha's therapeutic categories but serving as a much broader-portfolio incumbent rather than a focused generics manufacturer.
Direct peers
- Drugfield Pharmaceuticals: Nigerian pharmaceutical manufacturer of branded generics across anti-infectives, anti-malarials and supportive therapies; same Nigerian market context, comparable prescription-led distribution model and head-to-head competitor for Swipha's therapeutic categories.
- Emzor Pharmaceutical Industries: Leading Nigerian pharmaceutical manufacturer of branded generics across antibiotics, antimalarials and supportive therapies; comparable scale, Nigerian domestic focus and competing for share of the same prescription and OTC channels as Swipha.
- Fidson Healthcare Plc: Largest Nigerian-listed branded generics manufacturer producing prescription and consumer healthcare products across antibiotics, antimalarials, cardiovascular and nutraceuticals — directly comparable therapeutic portfolio, distribution model and Nigerian market focus.
- Neimeth International Pharmaceuticals Plc: Nigerian-listed pharmaceutical manufacturer with branded generics across cardiovascular, anti-infectives and nutraceuticals; comparable therapeutic breadth, single-country focus and prescription / consumer hybrid distribution.
- May & Baker Nigeria Plc: Nigerian pharmaceutical manufacturer (and historical Swipha management alumni pipeline via Technical Director Yetunde Adigun's prior role) producing branded generics across anti-infectives, anti-malarials and consumer health — directly comparable product mix and Nigerian market footprint.
Emerging players
- Emcure Pharmaceuticals: Indian generics manufacturer with active African footprint and growing WHO prequalification portfolio — a credible emerging competitor in West African tender and private generics markets where Swipha also competes.
Regional players
- Aspen Pharmacare Holdings: South African pharmaceutical manufacturer with the largest branded generics portfolio on the continent and active WHO prequalification footprint; comparable broad therapeutic categories and African manufacturing base, but operates primarily from a different geography.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Swipha social profiles
Digital presenceSwipha compliance and trust
Trust signalCompliance4 records
Swipha financial estimates
Financial estimateRevenue estimate
Valuation estimate
Swipha leadership team
Management profileNumber of profiles
Profiles9 records
Swipha funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Swipha M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Swipha
What does Swipha do?
Swipha (Swiss Pharma Nigeria Limited) manufactures and distributes a portfolio of over 50 SKUs and 30+ brands of prescription and consumer healthcare pharmaceutical products across five major therapeutic categories: Anti-diabetes, Anti-infectives, Anti-malarial, Central Nervous System, and Cardiovascular. The company operates a WHO cGMP-certified manufacturing facility in Lagos, Nigeria, producing WHO-prequalified medications and serving healthcare providers, pharmacies, and government health programs in Nigeria and West Africa.
Is Swipha a public or private company?
Swipha is a private company. It is classified as corporate owned and is currently operating.
When was Swipha founded?
Swipha was founded in 1976. It employs 5,001 to 10,000 people.
Where is Swipha based?
Swipha is headquartered in Lagos, Nigeria, in the Africa region.
How does Swipha make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Swipha's main competitors?
Broad incumbents on record are Sanofi Nigeria, Cipla (African operations) and GlaxoSmithKline (GSK Nigeria). Direct peers are Drugfield Pharmaceuticals, Emzor Pharmaceutical Industries, Fidson Healthcare Plc, Neimeth International Pharmaceuticals Plc and May & Baker Nigeria Plc. Emcure Pharmaceuticals is listed as an emerging player. Aspen Pharmacare Holdings is listed as a regional player.
Does Swipha have an API?
No public API is recorded for Swipha.
What industry is Swipha in?
Swipha's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 3254 and its SIC code is 2834.